Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingPremera Blue Cross AI Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera Blue Cross of WashingtonPolicy N/A

    Mammography-Based AI Breast Cancer Risk Prediction

    Customize your policy alerts

    Sign up for all premerabluecrossofwashington policy alerts

    Know when premerabluecrossofwashington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses artificial intelligence software applied to bilateral screening mammograms to estimate an individual's five-year risk of developing breast cancer. The service is considered investigational and unproven because evidence is insufficient to establish improved health outcomes.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyMammography-Based AI Breast Cancer Risk Prediction
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFeb 5, 2027
    Next Review DateN/A
    Key ActionWhen Clairity Allix5 is used, document that the input consisted of directly acquired bilateral 2D screening mammograms obtained from a validated Hologic Selenia Dimensions or Lorad Selenia mammography system.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy addresses mammography-based artificial intelligence risk prediction during bilateral screening mammography.

    The policy establishes that mammography-based artificial intelligence risk prediction software used to estimate 5-year breast cancer risk is investigational.

    5 yearsRisk prediction timeframe
    InvestigationalCoverage determination
    ≥35 yearsIncreased-risk pathway age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥1.7%
    Five-year invasive breast cancer risk threshold
    0.64Discrimination performance goal

    Coverage Criteria

    Mammography-based AI Risk Prediction

    The service is considered investigational and unproven.

    Mammography-based AI risk prediction: Use of mammography-based AI risk prediction software for individuals undergoing bilateral screening mammography to estimate their five-year risk of developing breast cancer is investigational because evidence is insufficient to show that it improves health outcomes.

    Validated Imaging Acquisition

    Clinical risk prediction with Clairity Allix5 requires use of its validated imaging acquisition profile.

    Clairity Allix5 validated input: The input must be directly acquired bilateral 2D screening mammograms obtained from Hologic Selenia Dimensions or Lorad Selenia mammography systems.Bilateral directly acquired 2D screening mammograms

    Synthetic 2D images, digital breast tomosynthesis-derived 2D images, and images from other manufacturers are outside the validated acquisition profile.

    Mammography-based AI Risk Prediction

    The described use is considered investigational.

    Investigational use: Mammography-based artificial intelligence risk prediction software is used for an individual undergoing bilateral screening mammography to estimate 5-year risk of developing breast cancer.

    The policy classifies this use as investigational.

    For Clairity Allix5 clinical risk prediction, the input must be directly acquired bilateral 2D screening mammograms from a validated Hologic Selenia Dimensions or Lorad Selenia mammography system. Synthetic 2D images, digital breast tomosynthesis-derived 2D images, and images acquired from other manufacturers are outside the validated acquisition profile and should not be used.

    Using more than one mammography-based AI risk prediction model to estimate five-year breast cancer risk is not indicated. A clinical risk prediction model may be used alongside a mammography-based AI model in subgroups where AI performance is less established; this limitation does not apply to clinical or comprehensive family-history-based risk models or genetic testing for hereditary breast cancer risk.

    Coding and Regulatory Identifiers

    Procedure InvestigationalCPTExperimental
    19499Unlisted procedure, breast
    Regulatory/device identifiersmixed
    DEN240047FDA De Novo classification for Clairity Allix5
    21 CFR 892.8500Radiological software device classification cited for Clairity Allix5
    SEZFDA product code for Clairity Allix5
    Increased-Risk Pathway Threshold
    Threshold≥1.7%
    MeasureFive-year risk of invasive breast cancer
    UseEntry threshold for the increased-risk management pathway
    Increased-Risk Pathway Age
    Threshold≥35 years
    PopulationIndividuals entering the increased-risk management pathway
    Assessment

    Provider Actions and Documentation

    Documentation Required

    Use Validated Image Acquisition

    When using Clairity Allix5 for clinical risk prediction, use directly acquired bilateral 2D screening mammograms from validated Hologic Selenia Dimensions or Lorad Selenia mammography systems.

    • Document that the bilateral 2D screening mammograms were directly acquired from a validated system.
    • Use only the imaging acquisition platforms and formats specified in the device authorization or published validation studies.
    Denial Risk

    Investigational AI Risk Prediction

    Mammography-based AI risk prediction software used during bilateral screening mammography to estimate a person's five-year risk of developing breast cancer is considered investigational (unproven).

    • There is insufficient evidence to establish that this use is effective.

    Policy Background

    Mammography-based AI risk prediction software analyzes bilateral screening mammograms to estimate an individual’s five-year risk of developing or being diagnosed with breast cancer. The software identifies imaging patterns and generates a risk estimate for use in risk assessment and management. The policy considers this use investigational because evidence is insufficient to demonstrate improvement in health outcomes; established clinical and family-history-based risk models remain relevant.

    Definitions and Abbreviations

    Definitions
    TermScreening mammography
    DefinitionAn X-ray examination of the breasts used to look for signs of breast cancer before symptoms develop.
    Body regionBreasts
    Definitions
    TermArtificial intelligence
    DefinitionComputer technology that analyzes large amounts of information and identifies patterns.
    Policy useUsed to analyze breast imaging and estimate five-year breast cancer risk.

    Covered Indications and Pathways

    Increased Breast Cancer Risk

    The increased-risk management pathway applies when both criteria are met.

    Increased-risk management pathway: The individual is at least 35 years of age and has a five-year invasive breast cancer risk of at least 1.7% calculated using the Gail Model or an imaging-based risk assessment model such as Clairity or Mirai.Age ≥35 years; five-year invasive breast cancer risk ≥1.7%

    The pathway includes clinical follow-up, annual mammography with tomosynthesis, risk-reduction counseling, and consideration of supplemental imaging.

    Five-Year Breast Cancer Risk Prediction Using Clairity Allix5

    The routine bilateral screening mammogram must contain all four standard 2D views.

    Required imaging input: Routine bilateral screening mammogram containing the four standard 2D views: RCC, LCC, RMLO, and LMLO.4 standard 2D views

    Frequency and Encounter Limits

    Frequency Limits
    ModalityScreening mammography with tomosynthesis
    FrequencyAnnual
    PeriodPer year
    Frequency Limits
    ServiceClinical encounter
    FrequencyEvery 6 to 12 months
    PurposeBreast cancer risk management

    Contrast and MRI Rules

    Billing Rule

    Consider contrast-enhanced supplemental imaging

    For individuals identified as having increased breast cancer risk, annual breast MRI with and without contrast may be considered. Contrast-enhanced mammography or molecular breast imaging may be considered for those who qualify for MRI but cannot undergo it; whole-breast ultrasound may be used when those modalities are unavailable.

    Not Covered Services

    Mammography-based AI risk prediction software used with bilateral screening mammography to estimate an individual’s five-year breast cancer risk is considered investigational and unproven. This use is not covered under the policy and may result in denial.

    Policy Summary
    PayerPremera Blue Cross of Washington
    PolicyMammography-Based AI Breast Cancer Risk Prediction
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFeb 5, 2027
    Next Review DateN/A
    Key ActionWhen Clairity Allix5 is used, document that the input consisted of directly acquired bilateral 2D screening mammograms obtained from a validated Hologic Selenia Dimensions or Lorad Selenia mammography system.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Regulatory IdentifiersProvider Actions and DocumentationPolicy BackgroundDefinitions and AbbreviationsCovered Indications and PathwaysFrequency and Encounter LimitsContrast and MRI RulesNot Covered Services
    Age is considered with five-year invasive breast cancer risk
    Discrimination Performance Goal
    Performance goalAUC[5] ≥0.64
    MeasureTime-dependent area under the curve at five years
    ApplicationPrespecified discrimination performance goal for Clairity Allix5
  1. The investigational designation applies to use for individuals undergoing bilateral screening mammography to estimate five-year breast cancer risk.
  2. Unsupported block type: denial_risk

    Note

    Do Not Use Multiple AI Models

    Using more than one mammography-based AI risk prediction model to estimate five-year breast cancer risk is not indicated.

    • A clinical risk prediction model may be paired with a mammography-based AI risk prediction model in subgroups where AI performance is less well established.
    • This limitation does not apply to clinical or comprehensive family-history-based risk-assessment models or to genetic testing for hereditary breast cancer risk.
    • Reassess risk periodically only when risk factors change.
    Denial Risk

    Mirai Is Not FDA Authorized

    Mirai has not been approved or cleared by the U.S. Food and Drug Administration and is for research purposes only until FDA authorization.

    • Do not use Mirai for authorized clinical risk prediction unless and until it receives FDA authorization.
    Documentation Required

    Document Investigational AI Use

    Mammography-based AI risk prediction software used during bilateral screening mammography to estimate a person's five-year risk of developing breast cancer is considered investigational (unproven).

    • Document the bilateral screening mammography context and the intended five-year breast cancer risk estimate.
    • Inform patients and care teams that evidence is insufficient to establish effectiveness for this use.
    Definitions
    TermFive-year breast cancer risk
    DefinitionThe estimated probability that an individual will receive a breast cancer diagnosis or develop breast cancer within five years.
    BasisCalculated from a bilateral screening mammogram.
    Definitions
    AbbreviationAFAB
    DefinitionAssigned female at birth
    TypeGlossary abbreviation
    Definitions
    AbbreviationAH
    DefinitionAtypical hyperplasia
    TypeGlossary abbreviation
    Definitions
    AbbreviationAMAB
    DefinitionAssigned male at birth
    TypeGlossary abbreviation
    Definitions
    AbbreviationBI-RADS
    DefinitionBreast imaging reporting and data system
    TypeBreast imaging glossary abbreviation
    Definitions
    AbbreviationBOADICEA
    DefinitionThe breast and ovarian analysis of disease incidence and carrier estimation algorithm
    TypeBreast cancer risk model abbreviation
    Definitions
    AbbreviationDCIS
    DefinitionDuctal carcinoma in situ
    TypeBreast disease abbreviation
    Definitions
    AbbreviationFNA
    DefinitionFine-needle aspiration
    TypeClinical procedure abbreviation
    Definitions
    AbbreviationLCIS
    DefinitionLobular carcinoma in situ
    TypeBreast disease abbreviation
    Definitions
    AbbreviationPRS
    DefinitionPolygenic risk score
    TypeRisk assessment abbreviation
    Definitions
    AbbreviationSNP
    DefinitionSingle nucleotide polymorphism
    TypeGenetic terminology abbreviation
    Definitions
    TermMammography-based AI risk prediction
    DefinitionArtificial intelligence software used with mammography to estimate an individual's 5-year risk of developing breast cancer.
    Imaging contextBilateral screening mammography

    Synthetic 2D images and images from non-Hologic acquisition platforms are not supported for Clairity Allix5.

    Five-Year Breast Cancer Risk Prediction Using Mirai

    The routine bilateral screening mammogram must contain all four standard 2D views.

    Required imaging input: Routine bilateral screening mammogram containing the four standard 2D views: RCC, LCC, RMLO, and LMLO.4 standard 2D views

    Mirai incorporates traditional or predicted risk factors in addition to mammographic image information.

    Estimation of Five-Year Breast Cancer Risk Using Mammography-Based AI

    The service involves bilateral screening mammography with AI-based five-year risk estimation.

    Bilateral screening mammography with AI risk prediction: The individual is undergoing bilateral screening mammography and mammography-based artificial intelligence software is used to estimate 5-year breast cancer risk.

    This use is considered investigational.